Healthy
Conditions
Brief summary
The objective of this study is to establish the tipranavir-ritonavir steady-state dose-exposure relationships when administered on a b.i.d. dosing regimen; to determine the effects of tipranavir (TPV) and ritonavir (RTV) on cytochrome P-450 (CYP3A4) activity; to establish the dependency of the TPV M1 metabolite on RTV co-administration. Additionally, the short-term safety and tolerance of this drug combination will be evaluated.
Interventions
DRUGTPV low 1
DRUGTPV low 2
DRUGTPV medium
DRUGTPV high 1
DRUGTPV high 2
DRUGRTV low
DRUGRitonavir high
DRUGRadiolabelled erythromycin
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female between 18 and 75 years of age inclusive * Female subjects of child-bearing potential are required to use a barrier contraceptive method for at least 3 months prior to administration of study medication, during study medication administration and for 30 days after the end of the study * Ability to swallow numerous large capsules without difficulty * A body mass index (BMI) between 19 and 29 kg/m2 * Signed informed consent prior to trial participation * Reasonable probability for completion of the study * Acceptable screening laboratory values that indicate adequate baseline organ function are required at the time of screening. Laboratory values are considered to be acceptable if severity is no higher than Grade 1 based on the AIDS Clinical Trials Group (ACTG) Grading Scale. All laboratory values \> Grade 1 are subject to approval by the BIPI clinical monitor * Acceptable medical history, physical examination, electrocardiogram, and chest X-ray are required prior to entering the treatment phase of the study * Willingness to abstain from alcohol for 48 hours prior to study Day 0 and abstain from alcohol for the duration of the study * Willingness to abstain from ingesting grapefruit or grapefruit juice for the duration of the study * Urine drug screen negative for drugs of abuse * Negative HIV serology * Negative for Hepatitis B surface antigen and Hepatitis C antibody
Exclusion criteria
* Female subjects who: * have a positive serum pregnancy test at Visits 1 or 2 OR * are breastfeeding * Receipt of any other investigational medicine for 30 days prior to Day 0 * Receipt of any known enzyme altering drug for 30 days prior to Day 0, grapefruit and grapefruit juice within 15 days prior to Day 0 and antibiotics within 10 days prior to Day 0 * Excessive cigarette smoking, defined as greater than 10 cigarettes per day * Blood or plasma donation within 30 days prior to Day 0 * Subjects with a seated systolic blood pressure either \< 100 mg Hg or \> 150 mm Hg; resting heart rate either \< 50 beats/min or \> 90 beats/min * Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering tipranavir or ritonavir to the subject * Subjects who have had an acute illness within 2 weeks prior to Day 0 * Subjects who are currently taking any over-the-counter drug within 7 days prior to Day 0, or who are currently taking any prescription drug that, in the opinion of the investigator in consultation with the BIPI medical monitor and pharmacokineticist, might interfere with either the absorption, distribution or metabolism of the test substances * Hypersensitivity to tipranavir, ritonavir or sulfonamide containing drugs * Evidence of active substance abuse that, in the investigator's opinion, could affect study adherence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Trough plasma concentration at steady state (Cmin,ss) | up to 24 hours |
| Maximum plasma concentration at steady state (Cmax,ss) | up to 24 hours |
| Time of maximum concentration (tmax) | up to 24 hours |
| Area under the plasma concentration time curve from 0 to 12 hours (AUC0-12) | up to 12 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Oral clearance (Cl/F) | up to 24 hours | — |
| Number of subjects with adverse events | up to 32 days | — |
| Apparent terminal half life (t1/2) | up to 24 hours | — |
| Percent of erythromycin metabolized per hour | up to 24 hours | Erythromycin breath test (ERMBT) |
| Number of subjects with clinically significant findings in laboratory tests | up to 32 days | — |
Outcome results
None listed